# Ionis Pharmaceuticals, Inc. clinical trials: 118 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 118 trials with Ionis Pharmaceuticals, Inc. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ionis Pharmaceuticals, Inc.: 118 rows for $5.90, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ionis-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 118
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 118, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 24, 2026 | NCT07782827 | CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS) | Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | Angelman Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782827) |
| July 27, 2026 | NCT07727538 | A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants | Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | Familial Chylomicronemia Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727538) |
| May 22, 2026 | NCT07604974 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Ionis Pharmaceuticals, Inc. | Phase 2 | Recruiting | Hypertriglyceridemia, Severe Hypertriglyceridemia | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604974) |
| April 15, 2026 | NCT07531745 | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Ionis Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Dravet Syndrome | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531745) |
| March 23, 2026 | NCT07487389 | Zilganersen Expanded Access Program for Individuals With Alexander Disease | Ionis Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Alexander Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487389) |
| December 23, 2025 | NCT07298447 | Donidalorsen Treatment in Children With Hereditary Angioedema | Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | Hereditary Angioedema (HAE) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298447) |
| April 6, 2025 | NCT06914609 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Ionis Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Angelman Syndrome | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06914609) |
| November 4, 2024 | NCT06673069 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down... | Ionis Pharmaceuticals, Inc. | Phase 1 | Terminated | Alzheimer Disease, Down Syndrome | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06673069) |
| May 28, 2024 | NCT06430385 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in... | Ionis Pharmaceuticals, Inc. | Phase 1/2 | Recruiting | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06430385) |
| May 16, 2024 | NCT06415448 | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema | Ionis Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Hereditary Angioedema | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06415448) |
| April 11, 2024 | NCT06360237 | Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) | Ionis Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Familial Chylomicronemia Syndrome | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06360237) |
| December 1, 2023 | NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 | Ionis Pharmaceuticals, Inc. | Phase 1/2 | Active not recruiting | Prion Disease | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06153966) |
| November 29, 2023 | NCT06150716 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants... | Ionis Pharmaceuticals, Inc. | Phase 1 | Recruiting | Pelizaeus-Merzbacher Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06150716) |
| October 10, 2023 | NCT06073587 | The CARDIO-TTRansform Scintigraphy Sub-study | Ionis Pharmaceuticals, Inc. | Observational | Completed | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06073587) |
| October 10, 2023 | NCT06073574 | CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | Ionis Pharmaceuticals, Inc. | Observational | Completed | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06073574) |
| August 28, 2023 | NCT06014541 | Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2)... | Ionis Pharmaceuticals, Inc. | Observational | Terminated | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06014541) |
| January 12, 2023 | NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Severe Hypertriglyceridemia | 885 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05681351) |
| December 28, 2022 | NCT05667493 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Ionis Pharmaceuticals, Inc. | Phase 3 | Enrolling by invitation | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05667493) |
| December 21, 2022 | NCT05659901 | Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease | Ionis Pharmaceuticals, Inc. | Observational | Recruiting | Pelizaeus-Merzbacher Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05659901) |
| November 9, 2022 | NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe... | Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis | 1,478 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05610280) |
| October 14, 2022 | NCT05579860 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult... | Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Participants | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05579860) |
| September 23, 2022 | NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia | Ionis Pharmaceuticals, Inc. | Phase 3 | Completed | Severe Hypertriglyceridemia | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05552326) |
| May 26, 2022 | NCT05392114 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | Ionis Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Hereditary Angioedema | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05392114) |
| May 2, 2022 | NCT05355402 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease... | Ionis Pharmaceuticals, Inc. | Phase 2 | Completed | Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05355402) |
| April 20, 2022 | NCT05337878 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants | Ionis Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Participants | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05337878) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 11 |
| Phase 2 | 44 |
| Phase 2/3 | 1 |
| Phase 3 | 25 |
| Not applicable | 6 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 86 |
| Active not recruiting | 10 |
| Recruiting | 9 |
| Terminated | 6 |
| Approved for marketing | 4 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 14 |
| Hypertriglyceridemia | 10 |
| Amyloidosis | 7 |
| Angioedemas, Hereditary | 6 |
| Familial hyperchylomicronemia syndrome | 6 |
| Hypertension | 5 |
| Cytomegalovirus Retinitis | 4 |
| HIV Infections | 4 |
| Acquired Immunodeficiency Syndrome | 3 |
| Angelman Syndrome | 3 |
| Acromegaly | 3 |
| Cardiomyopathies | 3 |
| AIDS-Related Opportunistic Infections | 3 |
| Diabetes Mellitus | 3 |
| Epilepsies, Myoclonic | 2 |
| Arthritis, Rheumatoid | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Atherosclerosis | 2 |
| Crohn Disease | 2 |
| Hepatitis C, Chronic | 2 |
| Kidney Failure, Chronic | 2 |
| Thalassemia | 2 |
| Amyloid Neuropathies, Familial | 2 |
| Obesity | 2 |
| Amyotrophic Lateral Sclerosis | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
- [Eastern European restaurants in the United States](https://specstream.ai/data/businesses/eastern-european-restaurants/united-states)
